All In Biotech

Drug Trial Radar · NCT06234956

Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age.

Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX as Heterologous Booster for the Prevention of Coronavirus Disease 2019 (COVID-19) in Adolescents From 12 Years to Less Than 18 Years of Age.

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

242

Actual

Start

Jun 8, 2023

Primary completion

Sep 9, 2025

Study completion Sep 9, 2025

Sponsor

Lead sponsor
Hipra Scientific, S.L.UIndustry
Sponsor type
Industry
Collaborators
Veristat, Inc.; VHIR; Asphalion
First posted
Jan 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase IIb, open-label, uncontrolled, multi-centre, non-inferiority clinical trial, to assess the safety and immunogenicity of BIMERVAX® as a heterologous booster dose in adolescents.

Conditions

  • SARS CoV 2 Infection

Interventions

  • BIMERVAXBiological

    One dose of 40μg of BIMERVAX, administered intramuscularly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in immunogenicity against Omicron BA.1Time frame: 14 days
  2. Changes in immunogenicity against Omicron BA.1Time frame: 14 days
  3. Incidence of solicited local and systemic reactions (Safety and tolerability of PHH-1V)Time frame: 7 days
  4. Incidence of unsolicited local and systemic adverse events (Safety and tolerability of PHH-1V)Time frame: 28 days
  5. Incidence of related adverse events and serious adverse events (Safety and tolerability of PHH-1V)Time frame: 1 year
  6. Incidence of adverse events of special interest (Safety and tolerability of PHH-1V)Time frame: 1 year
  7. Incidence of related medically attended adverse events (Safety and tolerability of PHH-1V)Time frame: 1 year
  8. Incidence of Grade 2, Grade 3 and Grade 4 changes in safety laboratory parameters (Safety and tolerability of PHH-1V)Time frame: 14 days

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Vall Hebron

    Barcelona, Barcelona, Spain

  • CAP Centelles

    Centelles, Barcelona, Spain

  • Hospital Josep Trueta

    Girona, Girona, Spain

  • CAP Peralada

    Peralada, Girona, Spain

  • Hospital HM Montepríncipe

    Boadilla del Monte, Madrid, Spain

  • Hospital La Paz

    Madrid, Madrid, Spain

  • Hospital HM Puerta del Sur

    Móstoles, Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.